Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism

Nephrology Dialysis Transplantation

Volumn 18, Issue 4, 2003, Pages 826-829

  Buysschaert, Martin ^a   Cosyns, Jean Pierre ^a   Barreto, Leonel ^a   Jadoul, Michel ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Fanconi syndrome; Hypercalcaemia; Hyperparathyroidism; Nephrotoxicity; Pamidronate; Tubulointerstitial nephritis

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; DILTIAZEM; FOLIC ACID; FUROSEMIDE; GLIQUIDONE; MOLSIDOMINE; PAMIDRONIC ACID; SALCATONIN; SIMVASTATIN;

AGED; ANAMNESIS; ARTICLE; CASE REPORT; DIAGNOSTIC IMAGING; DRUG MEGADOSE; DRUG WITHDRAWAL; ECHOGRAPHY; FANCONI RENOTUBULAR SYNDROME; FOLLOW UP; HUMAN; HYPERCALCEMIA; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; KIDNEY FAILURE; LABORATORY DIAGNOSIS; MALE; PATIENT TRANSPORT; PHYSICAL EXAMINATION; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

AGED; BIOPSY, NEEDLE; DIPHOSPHONATES; FANCONI SYNDROME; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM; IMMUNOHISTOCHEMISTRY; MALE; NEPHRITIS, INTERSTITIAL; PARATHYROID GLANDS; RISK ASSESSMENT; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER;

EID: 0346817417     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg044     Document Type: Article

References (8)

1. Fitton A, McTavish D. Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991; 41: 289-318
2. Berenson J, Rosen L, Vescio R et al. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 1997; 37: 285-290
3. . Bounameaux H, Schifferli J, Montani JP, Jung A, Chatelanat F. Renal failure associated with intravenous diphosphonates. Lancet 1983; 1: 471
4. Hoggarth C, Bennett R, Daley-Yates PT. The pharmacokinetics and distribution of pamidronate for a range of doses in the mouse. Calcif Tissue Int 1991; 49: 416-420
5. Cal JC, Daley-Yates PT. Disposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1, 1-biphosphonate (APD), in rats and mice. Toxicology 1990; 65: 179-197
6. Markowitz GS, Appel G, Fine P et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001; 12: 1164-1172
7. Lockridge L, Papac RJ, Perazella MA. Pamidronate-associated nephrotoxicity in a patient with Langerhans' histiocytosis. Am J Kidney Dis 2002; 40: E2.
8. Janssen van Doorn K, Neyns B, Van der Niepen P, Verbeelen D. Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases. Nephron 2001; 89: 467-468